The ARFGAP2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which ARFGAP2 has been disrupted by CRISPR/Cas9-mediated genome editing. This loss-of-function model provides a heterogeneous pool of edited HeLa cells, enabling studies of ARFGAP2-dependent processes without clonal selection bias. The polyclonal format is ideal for investigating collective cellular responses in intracellular trafficking and Golgi dynamics.
The HeLa host cell line is an immortalized human cervical adenocarcinoma epithelial cell line, HPV-18 positive, with functional inactivation of p53 and Rb by the viral oncoproteins E6 and E7. This well-characterized model supports robust secretion and membrane trafficking, making it a standard platform for cancer biology and cell signaling research. The adherent growth and active Golgi apparatus facilitate detailed examination of retrograde transport and glycosylation pathways.
ARFGAP2 encodes a GTPase-activating protein for ARF1 and ARF5 at the Golgi. It is recruited by ARF1-GTP and interacts with the COPI coat complex via ??-COP and ??-COP, as well as with the KDEL receptor (KDELR). By stimulating GTP hydrolysis, ARFGAP2 promotes COPI coat disassembly and retrograde vesicle formation, retrieving KDEL-containing ER-resident proteins such as BiP and calreticulin from the Golgi back to the endoplasmic reticulum. This activity is regulated by KDELR occupancy and Golgi stress signals, and is essential for maintaining Golgi structural integrity and the early secretory pathway.
ARFGAP2 disruption in HeLa cells likely impairs COPI-dependent retrograde transport, leading to Golgi fragmentation, altered glycosylation, and ER protein mislocalization. These phenotypes are relevant to cancer cell migration and invasion, as Golgi dynamics influence secretory and adhesive properties. Additionally, the model facilitates mechanistic studies of hereditary spastic paraplegia and congenital disorders of glycosylation, diseases associated with trafficking defects, by dissecting how ARFGAP2 loss impacts organellar crosstalk in an oncogenic background.
Researchers can employ this knockout model in co-immunoprecipitation of COPI subunits, immunofluorescence for Golgi markers (GM130, giantin), and fluorescent KDEL ligand uptake assays to measure retrograde transport. Western blotting, flow cytometry for cell surface glycosylation, and migration/invasion assays further enable functional phenotyping. Phosphoproteomics and electron microscopy provide deeper insight into Golgi stress signaling and ultrastructure. For additional information, please contact Ascent Research.
